Atlas Trials

Study to Assess the Bioequivalence of Ibrutinib 140 Milligram (mg) Tablet to 140 mg IMBRUVICA Capsule

Clinical trial NCT02877225 · COMPLETED

Trial details

NCT number
NCT02877225
Sponsor
Janssen Research & Development, LLC
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Healthy
Start date
2016-08-29
Primary completion
2016-11-11
Enrollment
103

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.